HPV31 and HPV33 incidence in cervical samples from women in Recife, Brazil

Genetics and Molecular Research

Volumn 8, Issue 4, 2009, Pages 1437-1443

  Baldez Da Silva, M F P T ^a   Chagas, B S ^a   Guimaraes V ^b   Katz, L M C ^b   Felix, P M ^c   Miranda, P M ^c   Lima, A A ^d   Arraes, L C ^a   Martins, D B G ^a   Lima Filho, J L ^a   Stocco, R C ^c   Crovella, S ^a,e   Freitas, A C ^a   Becak W ^c  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c INSTITUTO BUTANTAN   (Brazil)

^d FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^e UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Cervical cancer; Genotyping; Human papillomavirus; Prophylactic vaccines

Indexed keywords

ADULT; ARTICLE; BRAZIL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENOME; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; MAJOR CLINICAL STUDY; MORBIDITY; NONHUMAN; WART VIRUS;

ALPHAPAPILLOMAVIRUS; BRAZIL; CERVIX UTERI; FEMALE; HUMANS; POLYMERASE CHAIN REACTION; SPECIES SPECIFICITY;

HUMAN PAPILLOMAVIRUS;

EID: 73449103908     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/vol8-4gmr677     Document Type: Article

References (28)

1. Al-Daraji WI and Smith JH (2009). Infection and cervical neoplasia: facts and fiction. Int. J. Clin. Exp. Pathol. 2: 48-64.
2. Beçak W, Carvalho RF, Ruiz RM, Stocco RC, et al (2009). BPV-1 L1 expression in E. coli. Abstract Book of the 25th International Papillomavirus Conference Clinical and Educational Workshop, May 8-14, 2009, Malmö.
3. Calleja-Macias IE, Villa LL, Prado JC, Kalantari M, et al. (2009). Worldwide genomic diversity of the high-risk human papillomavirus types 31, 35, 52 and 58, four close relatives of human papillomavirus type 16. J. Virol. 79: 13630-1340.
4. Coimbra EC, Souza HM, Leitão MCG, Santos JF, et al. (2007). Virus-like particles as a vaccinal strategy against tumors induced by papillomavirus infection. Commun. Curr. Res. Educ. Topics Trends Appl. Microbiol. 2: 689-696.
5. Cubie HA (2007). Papillomaviruses and Polyomaviruses. In: Medical Microbiology (Greenwood D, Slack R, Peutherer J and Barer M, eds.). 17th edn. Churchill Livingstone Elsevier, United Kingdom, 45: 446-456.
6. Goés LGB, Freitas AC, Ferraz OP, Rieger TT, et al. (2008). Bovine papillomavirus type 4 L1 gene transfection in a Drosophila S2 cell expression system: absence of L1 protein expression. Braz. J. Microbiol. 39: 1-4.
7. Handisurya A, Schellenbacher C and Kirnbauer R (2009). Diseases caused by human papillomaviruses (HPV). J. Dtsch. Dermatol. Ges. 7: 453-466.
8. Hildesheim A, Markowitz L, Avila MH and Franceschi S (2006). Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines. Vaccine 24 (Suppl 3): S3/227-S3/232.
9. Instituto Nacional de Câncer (INCA) (2007). Estimativa 2008: Incidência de Câncer no Brasil. Ministério da Saúde, ISBN 978-7318-125-8, Rio de Janeiro. Available at [http://bvssp.icict.fiocruz. br/lildbi/docsonline/4/5/1454-estimativa-2008.pdf]. Accessed January 9, 2008.
10. Lorenzato F, Ho L, Terry G, Singer A, et al. (2000). The use of human papillomavirus typing in detection of cervical neoplasia in Recife (Brazil). Int. J. Gynecol. Cancer 10: 143-150.
11. Lowndes CM (2006). Vaccines for cervical cancer. Epidemiol. Infect. 134: 1-12.
12. Massad LS, Einstein M, Myers E, Wheeler CM, et al. (2009). The impact of human papillomavirus vaccination on cervical cancer prevention efforts. Gynecol. Oncol. 114: 360-364.
13. Mendez F, Muñoz N, Posso H, Molano M, et al. (2005). Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J. Infect. Dis. 192: 1158-1165.
14. Parkin DM and Bray F (2006). Chapter 2: The burden of HPV-related cancers. Vaccine 24 (Suppl 3): S3/11-S3/25.
15. Pyeon D, Pearce SM, Lank SM, Ahlquist P, et al. (2009). Establishment of human papillomavirus infection requires cell cycle progression. PLoS. Pathol. 5: e1000318.
16. Rama C, Roteli-Martins C, Derchain S, Longatto-Filho A, et al. (2008). Previous screening for cervical cancer among women with cytological and histological abnormalities. [Rastreamento anterior para câncer de colo uterino em mulheres com alterações citológicas ou histológicas]. Rev. Saúde Pública 42: 411-419.
17. Rambout L, Hopkins L, Hutton B and Fergusson D (2007). Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 177: 469-479.
18. Ruiz RM, Sircili MP, Campo MS, Beçak W, et al. (2009). Avaliação imunológica preliminary da utilização da proteína recombinante L2 do papilomavírus bovino. Available at [http://200.136.53.130:13580/cdrom/2009/sbm/cd/resumos/R2298-1.html]. Accessed November 23, 2009.
19. Silva AMTC, Amaral AMVT and Cruz AD (2006). HPV e Câncer: O papel do papiloma vírus humano na carcinogênese. Biotecnol. Cienc. Desenvolv. 29: 48-54.
20. Stanley MA (2001). Human papillomavirus and cervical carcinogenesis. Best Pract. Res. Biotecnol. Cienc. Desenvolv. 29: 20-22.
21. Szalmás A and Kònya J (2009). Epigenetic alterations in cervical carcinogenesis. Semin. Cancer Biol. 19: 144-152.
22. Trottier H and Franco EL (2006). The epidemiology of genital human papillomavirus infection. Vaccine 24 (Suppl 1): S1-S15.
23. Wang SS, Zuna RE, Wentzensen N, Dunn ST, et al. (2009). Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol. Biomarkers Prev. 18: 113-120.
24. Wood D, Shin JH, Duval B and Schmitt HJ (2006). Chapter 22: Assuring the quality, safety and efficacy of HPV vaccines: the scientific basis of regulatory expectations pre- and post-licensure. Vaccine 24 (Suppl 3): S3/187-S3/192.
25. Woodman CBJ, Collins SI and Young LS (2007). The natural history of cervical HPV infection: unresolved issues. Nat. Rev. Cancer 7: 11-22.
26. Wright TC, Bosch FX, Franco EL, Cuzick J, et al. (2006). Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine 24 (Suppl 3): S3/251-S3/261.
27. Yalti S, Gurbuz B, Bilgic R, Cakar Y, et al. (2005). Evaluation of cytologic screening results of the cervix. Int. J. Gynecol. Cancer 15: 292-294.
28. zur Hausen H (2006). Perspectives of contemporary papillomavirus research. Vaccine 24 (Suppl 3): S3/iii-S3/iiv.